Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colombe Chappey

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Cancer Research Communications|April 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley StudyDuncan A Wheatley, Rossana Berardi, Miguel A Climent Duran, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic TrialAlison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Nature|March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancerAnton Safonov, Minna Lee, David N Brown, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Cancer Research Communications|April 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley StudyDuncan A Wheatley, Rossana Berardi, Miguel A Climent Duran, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic TrialAlison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Nature|March 4, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancerAnton Safonov, Minna Lee, David N Brown, et al.
Pageof 4